In bronchiectasis, due to diseases other than cystic fibrosis, idiopathic, genetic and environmental factors alter the airway landscape and immune responses, rendering the patients susceptible to infection, with the Gram-negative bacterium (GNB) Pseudomonas aeruginosa as a major contributor to mortality [1, 2]. The high prevalence of P. aeruginosa in bronchiectasis patients cannot be explained by a single genetic or environmental influence, and immunological permissiveness of bronchiectasis airways to this colonisation remains unexplained [2]. A similar predisposition to this pathogen is characteristic of cystic fibrosis patients, in whom a single genetic mutation (CFTR) shapes the abnormal lung environment. Large subpopulations of patients with bronchiectasis due to diseases other than cystic fibrosis (∼50% in two independent cohorts) develop autoantibodies to BPI, which arise specifically in the context of chronic Pseudomonas aeruginosa infection http://ow.ly/1LHZ30mtfXu
No takes yet. Share an insight, caveat, or question.
Skopelja‐Gardner et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: